Ovarian PRP Injections for Improved Embryo Quality Using Embryo Quality Score

Launched by GENERATION NEXT FERTILITY · Jun 10, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment for women facing challenges with infertility, particularly those with poor ovarian reserve or issues with embryo development during in vitro fertilization (IVF). The study will involve giving patients special injections called ovarian PRP (platelet-rich plasma), which are believed to improve the quality of embryos. Researchers will closely monitor how the embryos develop using advanced imaging technology and artificial intelligence.

To be eligible for this trial, participants need to be women aged between 18 and 44 years who have enough healthy eggs and are willing to go through two IVF cycles along with the PRP treatment. It's important to note that women who are in menopause or have certain health conditions that could interfere with IVF or PRP are not able to join. While the trial is not yet recruiting participants, those who join can expect to play a role in advancing knowledge about fertility treatments, with the hope of improving outcomes for future patients.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • No none contraindications to IVF or PRP treatment
• • Adequate ovarian reserves and AMH level
• • Willingness to undergo two IVF cycles and oPRP treatment
• Exclusion Criteria:
• • Anovulation due to menopause or perimenopause
• • Any health conditions that are contraindicated for IVF or oPRP treatment